Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Clonal hematopoiesis in cancer

Project description

The role of clonal hematopoiesis in cancer progression

Clonal hematopoiesis of indeterminate potential (CHIP) is a condition in which blood-forming stem cells acquire mutations that allow certain clones to expand, even though no blood cancer is present. CHIP becomes more common with age and increases the risk of blood malignancies, inflammatory diseases and poorer outcomes in cancer patients. Individuals with solid tumours show higher rates of CHIP and face an elevated risk of developing aggressive therapy-related blood cancers. The ERC-funded CHIC project aims to understand how CHIP influences cancer progression and immune interactions, and how it may lead to treatment-related complications. Researchers will combine genomics, artificial intelligence and cancer biology to develop tools for early CHIP detection and for tracking its evolution.

Objective

Clonal hematopoiesis (CH) is the expansion of somatically mutated hematopoietic stem cells. Clonal hematopoiesis of indeterminate potential (CHIP) occurs when CH is driven by mutations in myeloid driver genes in individuals without hematologic disorders. CHIP increases the risk of hematological malignancies and chronic inflammatory diseases. CHIP is also associated with a higher incidence of non-hematological malignancies, such as lung cancer. These associations underline the importance of CHIP in the development of both malignant and non-malignant diseases.

Patients with cancer have higher prevalence of CHIP compared to the general population and are at risk of developing therapy-related myeloid neoplasms (t-MN). As the prognosis of t-MN patients is poor, identifying and managing cancer patients with CHIP at risk of developing t-MN is critical. Moreover, patients with solid tumors and CHIP have an excess mortality not fully explained by increased rates of hematologic or cardiovascular diseases. Thus, a knowledge gap remains in understanding the role of CHIP in cancer, both in solid tumor progression and as a precursor to high-risk t-MN.

I propose to address key challenges in four interconnected areas of (1) early detection of CHIP, (2) systemic role of CHIP at the solid tumor-immune interface, (3) interception of CHIP evolution, and (4) precision diagnostics at progression to t-MN, using a multidisciplinary approach at the intersection of computational genomics, artificial intelligence, myeloid cell tumor biology, and precision oncology. I will develop tools for the early detection of CHIP during routine clinical care, elucidate the role of CH in tumor evolution, identify mediators of CHIP evolution towards t-MN, and define a novel molecular t-MN classification. This project has the potential to transform our understanding and management of CHIP in cancer.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

INSTITUT GUSTAVE ROUSSY
Net EU contribution
€ 1 500 000,00
Address
Rue Camille Desmoulins 39
94805 Villejuif
France
Region
Ile-de-France Ile-de-France Val-de-Marne
Activity type
Research Organisations
Links
Total cost
€ 1 500 000,00

Beneficiaries (1)